← All trials
NCT04303520
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 3, 2018
- Primary completion
- Sep 30, 2020
- Completion date
- Feb 28, 2021
- First posted
- Mar 11, 2020
- Last posted
- Mar 11, 2020
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Henan Medical UniversityLead sponsor
- Nanchang UniversityCollaborator
- Hrain Biotechnology Co., Ltd.Collaborator
- Wenzhou Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.